DataMeds AI Regains Compliance With Nasdaq Equity Rule

 DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated October 19, 2026, informing DataMEDS that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). In order to regain compliance with the Equity Rule, DataMEDS needed to have a minimum stockholders' equity of $2.5 million.

The Company originally received a notice of delisting from NASDAQ on April 13, 2026 outlining the basis for delisting proceedings:

1)

Failure to meet minimum $1.00 bid-price; and
2)

Failure to maintain a minimum of $2,500,000 in stockholder's equity.
NASDAQ notified the Company on June 9, 2026 that it had regained bid-price compliance and provided the Company additional time to attempt to regain compliance with the minimum stockholders' equity requirement.

Based on a Company Form 8-K filing on October 13, 2026 that confirmed the Company's stockholder's equity exceeded $2,500,000 and a subsequent Form 8-K filing on October 16, 2026 that provided additional details on the material events that resulted in the Company exceeding $2,500,000 in stockholders' equity, on October 19, 2026 NASDAQ confirmed that the Company was in compliance with the Equity Rule. If the Company fails to evidence compliance upon filing its next periodic report it may be subject to delisting.